Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/28/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
11/09/2022* -- Results Q3 2022 -- -0.57 --
08/08/2022 -- Results Q2 2022 -0.58 -0.42 -40.28%
05/05/2022 -- Results Q1 2022 -0.50 -0.44 -16.00%
02/28/2022 -- Results Q4 2021 -0.46 -0.38 -20.43%
02/28/2022 16:30 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 -0.37 -0.35 -7.41%
08/05/2021 -- Results Q2 2021 -0.34 -0.40 15.70%
*Estimated Date/Time

Earnings

Next Report Date 11/09/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/08/2022
Beat/Miss Upgrade
Return Since -24.98%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
URL https://www.celldex.com
Investor Relations URL https://ir.celldex.com
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-14.08%
-77.42%
-19.77%
-93.03%
-24.88%
685.7%
120.5%
-27.25%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-23.87%
--
--
--
--
--
--
-88.16%
-74.19%
--
-48.62%
-9.38%
25.12%
-72.37%
-54.50%
13.15%
-88.69%
-29.63%
-52.07%
-43.76%
-71.37%
-38.63%
70.63%
-53.49%
-74.70%
-35.79%
-38.13%
-31.16%
-24.87%
108.1%
-27.93%
-13.82%
-40.72%
As of September 30, 2022.

Profile

Edit
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
URL https://www.celldex.com
Investor Relations URL https://ir.celldex.com
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ETCHX 38.98M USD 2.95%
FIJYX 26.79M USD 1.64%
AHSCX 2.827M USD 1.53%
IWC 2.578M USD 0.31%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CLDX Tweets